Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

FDA Accepts sNDA for Zanubrutinib in Waldenström Macroglobulinemia

The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for zanubrutinib for the treatment of adult patients with...

Crizotinib Approved for Relapsed/Refractory Systemic ALCL

Crizotinib has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of children older than one year and young adults...
On location

No Difference in CNS Relapse Rate According to Prophylaxis Route

According to results from a retrospective analysis of central nervous system (CNS) prophylaxis in patients with aggressive non-Hodgkin lymphomas (NHLs), rates of CNS relapse...

Can Adding Lenalidomide to Rituximab-MiniCHOP Improve Survival in Older Patients With Diffuse Large B-Cell...

In a phase III trial of patients age 80 or older with diffuse large B-cell lymphoma (DLBCL), attempts to improve on the standard approach...
WIB_icon

Risk of Subsequent Malignant Neoplasms Is Low in Children With Hodgkin Lymphoma

A study published in Blood suggests that children and adolescents with intermediate-risk Hodgkin lymphoma have a relatively low cumulative risk of developing subsequent malignant...

Predicting CAR T-Cell Treatment Failure in Patients With Aggressive B-Cell Lymphomas

Nearly one-half of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are treated with chimeric antigen receptor (CAR) T-cell therapy experience a relapse...
On location

Researchers Validate Burkitt Lymphoma Prognostic Index

Researchers have created a prognostic index specific to Burkitt lymphoma (BL) that will allow for simplified stratification and comparison of risk distribution in geographically...

Use of Transplant Persists as Appropriate Option in PTCLs

Backed by experience, but not randomized data, most institutions have established practices for transplant in patients with peripheral T-cell lymphomas. No consensus exists on the...

Moving Beyond Gene Rearrangements to Define High-Risk Diffuse Large B-Cell Lymphoma

In diffuse large B-cell lymphoma (DLBCL), patients typically are risk-stratified according to cell-of-origin, but recent genetics-based classifications led the World Health Organization to establish...
On location

Thiotepa-Containing Conditioning Regimens Improve Survival Outcomes in Patients With PCNSL

Thiotepa-containing conditioning regimens, including thiotepa/busulfan/cyclophosphamide (TBC) and thiotepa/carmustine (TT-BCNU), were associated with favorable survival outcomes in patients with primary diffuse large B-cell lymphoma of...